Dow Jones
38.359,13 -144,56 (-0,38%) Nasdaq
15.646,60 -50,04 (-0,32%) Nikkei 225
38.460,08 +907,92 (+2,42%) EUR/USD
1,0688 -0,0016 (-0,15%) Bitcoin EUR
60.245,11 -2.134,34 (-3,42%) CMC Crypto 200
1.398,80 -25,30 (-1,78%)
AnaptysBio, Inc. (0HFQ.L)
| Chiusura precedente | 19,57 |
| Aperto | 19,17 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 18,94 - 19,17 |
| Intervallo di 52 settimane | 13,80 - 27,27 |
| Volume | |
| Media Volume | 169 |
| Capitalizzazione | 4,355M |
| Beta (5 anni mensile) | -0,29 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,76 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAnaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032’s Phas
- GlobeNewswire
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25. Independent medical experts and members of Anaptys senior management will discuss: PD-1 biology and rosnilim
- GlobeNewswire
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131)Demonstrated favorable safety and tolerability with no SAEs, low incidence and no increase of infections vs. placebo and no cases of DRESS or Guillain-Barre in imsidolimab-treated patientsOnly one of 30 (3.3%) imsidolimab-treated patients had detectable ADA, which were non-neutralizingPlan to present comp
